ImmunoPrecise Antibodies (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™ bispecific program- platforms that blend seamlessly with IPA’s Artemis Intelligence Metadata (AIM)™ capabilities to enable rapid turnaround on additional algorithmic outputs in therapeutic optimization, stability, affinity and manufacturability.
IPA is focused on the next generation of antibody discovery, to deliver therapeutically relevant antibodies, in a short period of time, with high probability of succeeding to clinical trials. With over 30 years of experience in the custom antibody business, we have completed roughly 4000 projects for hundreds of clients across the globe, including a majority of the top 20 largest pharmaceutical companies.
Our discovery and development are conducted in Utrecht and Oss, the Netherlands (IPA Europe), and Victoria, British Columbia (IPA Canada) with headquarters located in Fargo, North Dakota. We operate multi-nationally to offer a continuum of antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.
We are comprised of experienced research and development scientists that encompass a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs.